Treatment with the EZH2-inhibitor tool compound 3-deazaneplanocin A (DZNep)17 or the clinically approved tazemetostat18, increased PGC1α expression (Fig. 1h; Supplementary Fig. 2c, d), and functionally decreased melanoma cell migration (Supplementary Fig. 2e). This evidence concerns the gene PPARGC1A and melanoma.